Highlights

• Expanding DAYBUE royalties lifted revenue despite weaker bottom-line performance.
• Clinical investment surged as the Koala Phase 3 program gathered pace.
• International commercial growth could unlock further royalties and milestone payments.

Neuren Pharmaceuticals Limited (ASX: NEU) published its H1 2026 financial results on 26 August 2026, revealing contrasting trends across its business. Income benefited from rising DAYBUE sales, while heavier expenditure on the company’s drug-development pipeline placed considerable pressure on earnings.

Higher Income Fails to Prevent Profit Decline

Revenue from ordinary activities reached AU$42.75 million for the six months ended 30 June 2026, an 8% increase from AU$39.72 million in H1 2025. The main contributor was royalty income from Acadia Pharmaceuticals, which rose 29% in US dollar terms to US$23.30 million. In Australian dollars, the improvement was 17%.

However, profit attributable to shareholders dropped 68% to AU$4.85 million, compared to AU$15.03 million a year earlier. Basic earnings per share declined from 11.88 cents to 3.83 cents, reflecting the impact of higher development spending.

Research and development costs increased by AU$12.50 million to AU$27.40 million. Much of this expenditure supported the Koala Phase 3 trial assessing NNZ-2591 in children with Phelan-McDermid syndrome. Interest income of AU$5.60 million exceeded corporate and administration expenses of AU$3.00 million.

Strong Liquidity Funds Clinical Ambitions

Cash and short-term investments stood at AU$287 million at the end of June 2026. This financial position allows Neuren to continue funding its NNZ-2591 programs, including the Phelan-McDermid syndrome development plan, for which expected expenditure remains within the previously indicated US$80–US$90 million range.

The company also introduced a dividend policy supported by its royalty stream. A fully franked interim dividend of AU$0.15 per share was declared, equal to 90% of the AU$21.10 million available distribution pool.

DAYBUE Broadens Its Commercial Reach

Global DAYBUE sales generated by Acadia increased 25% to US$226 million from US$180.70 million. Acadia subsequently lifted its 2026 sales guidance to US$480–US$510 million, leading Neuren to forecast annual royalties of US$53–US$56 million.

European approval creates another route for expansion, with the German launch expected in early Q4 2026. Neuren could qualify for a US$35 million payment once DAYBUE records its initial commercial sale in Europe.

Outlook Hinges on Execution

Koala now has 15 enrolling locations across the United States and Canada. A scheduled FDA meeting in late October will also address the proposed development pathway for NNZ-2591 in Pitt Hopkins syndrome.

Neuren’s liquidity and rising royalties provide a solid funding base. Nevertheless, near-term profitability may remain subdued as clinical expenditure increases, making trial progress and DAYBUE’s overseas expansion central to the company’s outlook.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au